Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by amritadaniqueon Oct 24, 2023 11:48am

71 Views

Post# 35698308

Bioxytran: Leading Healthcare Innovation Efforts

With a market capitalization of over $24.4 million and a remarkable 144,355,355 outstanding shares, Bioxytran is making substantial strides in the biotech industry. Their focus on tackling critical medical challenges demonstrates a commitment to pioneering innovative pharmaceutical solutions. As indicated by a strong 30-day average volume of 152,694, there is growing interest in Bioxytran's transformative medical solutions.

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement